LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The ...

Please provide your email address to receive an email when new articles are posted on . In patients with autoimmune pulmonary alveolar proteinosis, daily administration of inhaled molgramostim for 24 ...

Description: Effrosyni D. Manali, M.D., Ph.D., Maria Molina-Molina, M.D., Ph.D., and Maria Kokosi, M.D. will provide an update on autoimmune pulmonary alveolar ...

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte–macrophage ...

Poster Title: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial Session: English Poster Discussion “Rare ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

IN TODAY’S MEDICAL ALERT, THERE ARE 10,000 KNOWN RARE DISEASES. THEY IMPACT 30 MILLION PEOPLE IN THE US. FREDERICK COUNTY MAN IS ONE OF THEM. THESE SHARING HIS STORY OF SURVIVAL TO RAISE AWARENESS AND ...

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two ...

Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and ...